Best in Class Care entered an agreement with Regenexx to reduce high-cost musculoskeletal surgeries and accelerate employers' ability to directly contract with its network of providers.
Biologics
The Seattle Regenerative Medicine Center opened a new location in Bellevue, Wash.
Baxter International received FDA clearance for its Actifuse Flow bone graft substitute.
Mark Mikhael, MD, is studying the use of proteins from donor stem cells in spinal fusion surgery, Chicago Health reports.
Market analysts predict the spine biologics market will top $2.6 billion by 2022, growing at a 4.4 percent compound annual growth rate, according to a Market Research Engine report.
Advertisement
SpinalCyte received a U.S. patent for its cartilage repair technology using an in vivo bioreactor.
While the use of biologics in spine surgery is still emerging, more spine surgeons are gaining exposure to the field as new clinical trials and noninvasive treatments are born.
InVivo Therapeutics released the 12-month results of its investigational study of the Neuro-Spinal Scaffold to treat acute thoracic complete spinal cord injury.
Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis.
Isto Biologics is an orthobiologics company that develops spine and orthopedic solutions.